CND’s Dr. Todd Levine Talks to Neurology Live® at AAIC 2025
At the 2025 Alzheimer’s Association International Conference (AAIC) held last month in Toronto, Canada, Dr. Todd Levine spoke to Neurology Live about the latest findings from CND’s ongoing clinical studies of the Syn-One Test®.
“I think the exciting developments over the past year have been the ability to use the Syn-One Test to look earlier into the disease state,” said Dr. Levine, who highlighted key findings presented at medical conferences this year.
At the annual Sleep Meeting in June, CND Life Sciences presented data from the Syn-Sleep Study, which showed that the Syn-One Test detected phosphorylated alpha-synuclein (P-SYN) in 75% of patients with idiopathic REM sleep behavior disorder, a condition that is often an early indicator of Parkinson’s disease.
At the American Academy of Neurology meeting in April, CND presented baseline data from the Syn-D Study showing phosphorylated alpha-synuclein could be detected in the skin biopsies of patients with dementia with Lewy bodies even at the mild cognitive impairment stage. This finding sets the stage for earlier diagnosis and potential disease intervention, even years before a patient has progressed to the point of a dementia.
“Earlier and earlier detection has really been the key,” said Dr. Levine. “If you wait until someone has dementia … or Parkinson’s that is very advanced, it’s going to be very difficult to treat those diseases.” Although disease-modifying treatments are lacking for these neurological conditions, early interventions utilizing cognitive training and lifestyle modifications such as diet and exercise have demonstrated an ability to slow disease progression.
